Pàgina inicial > Resultats de la cerca: European Journal of Haematology
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 3 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
11 p, 396.3 KB Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics / Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ; Schjesvold, Fredrik (University of Oslo) ; Weisel, Katja (University Medical Center Hamburg-Eppendorf) ; Moreau, Philippe (University Hospital Hôtel-Dieu) ; Anderson, Larry D. (University of Texas Southwestern Medical Center) ; White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Sonneveld, Pieter (Erasmus MC Cancer Institute) ; Engelhardt, Monika (Universitätsklinikum Freiburg) ; Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Corso, Alessandro (Hospital of Legnano) ; Dürig, Jan (University Hospital Essen (Alemanya)) ; Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ; Salomo, Morten (Copenhagen University Hospital) ; Beksac, Meral (Ankara University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ; Liberati, Anna Marina (University of Perugia) ; Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ; Robak, Pawel (Medical University of Lodz) ; Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ; Yagci, Munci (Gazi University Medical Faculty) ; Vural, Filiz (Ege University) ; Kanate, Abraham (West Virginia University) ; Jiang, Ruiyun (Bristol Myers Squibb) ; Grote, Lara (Bristol Myers Squibb) ; Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ; Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83  
Registre complet - Creative Commons
2.
9 p, 982.6 KB Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis / Spicka, Ivan (Charles University and General Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Facon, Thierry (Lille University Hospital) ; Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital) ; Lim, Andrew (Austin and Repatriation Medical Center) ; Mikala, Gabor (South Pest Central Hospital) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Yağci, Münci (Gazi University) ; Cavo, Michele (Università di Bologna) ; Risse, Marie-Laure (Sanofi (França)) ; Asset, Gaëlle (Sanofi (França)) ; Macé, Sandrine (Sanofi (França)) ; Van de Velde, Helgi (Sanofi) ; Yong, Kwee (University College Hospital) ; Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512  
Registre complet - Creative Commons
3.
8 p, 354.8 KB A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma / Hájek, R (Faculty of Medicine. University of Ostrava) ; Pour, L. (University Hospital Brno (República Txeca)) ; Ozcan, M. (Ankara University School of Medicine) ; Martin Sánchez, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García Sanz, R. (Hospital Universitario de Salamanca) ; Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cascavilla, N. (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ; Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ; Briso, E. M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ; Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem